On July 2, 2025, Invivyd, Inc. announced the formation of the SPEAR Study Group with leading researchers to evaluate monoclonal antibody therapy's impact on Long COVID and post-vaccination syndrome. This initiative aims to enhance treatment understanding in these areas.